Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on Saturday, May 31 st , 2025 Theriva senior management to attend the ASCO conference and participate in an off-site investigator meeting to review the topline data from the VIRAGE Phase 2b... Read More